Komori
Governance4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

[First Half] Integrated Report "ASKA_HD_REPORT_2026"

The company states that it transitioned to a company with an audit and supervisory committee in 2026, shortened directors’ terms of office and raised the proportion of outside directors to a majority. It also formulated the long-term vision “ASKA VISION 2035” and Medium-Term Management Plan 2028, setting out the direction of its growth strategy and governance enhancement.

Worth reading
80Important
Scored from 2 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Committee1
ESG Committee
Policy on cross-shareholdings

Advanced the sale of cross-held shares and idle assets.

Policy regarding shares of other companies held to maintain business relationships and for other purposes.

Changes this time

In 2026, transitioned to a company with an audit and supervisory committee, shortened directors’ terms of office and raised the proportion of outside directors to a majority.

Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
CommitteeESG Committee (proportion of outside members: Not disclosed)
Policy on cross-shareholdingsAdvanced the sale of cross-held shares and idle assets.
Changes this timeIn 2026, transitioned to a company with an audit and supervisory committee, shortened directors’ terms of office and raised the proportion of outside directors to a majority.
Items this document does not state (4)
Number of directorsNumber of independent officersTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To further enhance management transparency and objectivity, achieve higher-quality decision-making and thereby increase corporate value.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
[First Half] Integrated Report "ASKA_HD_REPORT_2026" | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori